We meticulously assess clinical needs both domestically and internationally to initiate projects with a clear focus on differentiation in targets and technology. Our primary attention is on high-impact areas like lung cancer, pancreatic cancer, and gastrointestinal tumors, addressing the significant morbidity and mortality rates associated with these cancers globally.
Technology Innovation
Innovation is at the heart of Puhe. We integrate cutting-edge technologies such as the latest generation of kinases, allosteric inhibition, and synthetic lethality. Our approach hinges on a clear understanding of the mechanisms of action and high selectivity, enhancing drug efficacy while minimizing toxicity.
Innovation Platform
Optimization for efficiency. We focus on reducing development costs and enhancing operational efficiency through a flexible and innovative model. This approach allows us to efficiently advance our product pipeline, maintaining our commitment to bringing transformative healthcare solutions to market.
Product Pipelines
Drug TypePipeline CodeTargetIndicationLead CompoundPCCPreclinicalINDPhase IPhase IIPhase IIINDA
Cancer Therapy
PH001
EGFR exon20ins/T790M/19Del/L858R
First-line NSCLC exon20ins
2026
BTD
PH005
SHP2
Solid tumors with changed MAPK signal
PH009
EGFR C797S/T790M/19Del/L858R
NSCLC
PH020
PRMT5
Solid tumors with MTAP del
PH027
WRN
Solid tumors with dMMR/MSI-H
PH013
NA (Precision Medicine)
Solid tumors
Tumor Supportive Therapy Field
PH002
NA
VEGFRi-induced hand-foot syndrome
2026
PH003
NA
EGFRi-induced rash
Patient Recruitment
Recruiting non-small cell lung cancer patients with EGFR exon20ins
Indications: Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutation that has not received prior systemic anti-tumor therapy
Investigational drug: YK-029A tablets
Age requirement: 18-75 years old (including boundary values)
Number of recruited subjects: unlimited
Region: Anhui/ Beijing/ Fujian/ Gansu/ Guangdong/ Guangxi/ Guizhou/ Hebei/ Heilongjiang/ Henan/ Hubei/ Hunan/ Jiangsu/ Jiangxi/ Jilin/ Liaoning/ Shandong/ Shanghai/ Shanxi/ Shaanxi/ Sichuan/ Tianjin/ Xinjiang/ Yunnan/ Zhejiang/ Chongqing
